Allegro shares promising preclinical results for osteoarthritis treatment
Allegro Biotech has announced that hydrocelin (ALG-001), its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies. Allegro is a biomedical company that develops nanotechnology-based treatments for degenerative joint disease.
The preclinical studies were conducted in rats for periods of four and 13 weeks, respectively. Hydrocelin was injected into four separate locations, and a negative control group received saline solution. There was no evidence of systemic toxicity in either study.
Lucas Decuypere, Allegro’s chief executive officer, stated: “It is gratifying to be able to announce another set of positive results as we near a first-in-human testing for hydrocelin. Allegro is working tirelessly to give mobility back to the millions of people around the world whose life is severely impacted by osteoarthritis, a disease for which there is not currently a disease-modifying treatment. We believe the unique properties of hydrocelin, if confirmed in clinical studies, could be a huge step in achieving that goal.”
The positive safety results confirmed what the company had established in previously published preclinical studies. Allegro is planning a multi-centre clinical study later in 2025, preparing hydrocelin for osteoarthritis patients. Also, it intends on a commercial launch in 2027.
About hydrocelin (ALG-001)
Hydrocelin is an injectable microparticle hydrogel designed as a potential disease-modifying treatment for osteoarthritis. The biodegradable gel is an inert biocomposite, which confers unique mechanical properties and naturally self-reassembles. Forming a porous cell-friendly 3D scaffolding structure, the cross-linked microparticles may act as tiny shock absorbers in the synovial fluid, even under demanding conditions. By restoring elasticity, hydrocelin should enhance impact absorption and optimize load distribution. It is designed to provide pain relief, protect cartilage, and promote joint homeostasis. The treatment is minimally invasive.
About Allegro NV
Allegro is a private biomedical company developing transformative treatments for degenerative joint diseases based on its proprietary nanotechnology platform, INTRICATE. The company’s lead product candidate, hydrocelin (ALG-001), is a potential first-in-class, disease-modifying candidate for the treatment of osteoarthritis. Allegro is preparing hydrocelin for clinical studies in humans later this year, and for a commercial launch in 2027.
